• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类药物使用障碍的康复:一项临床研究结束 4 年后的结局研究。

Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.

机构信息

Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, 1 Riverside Circle, Roanoke, VA 24016, United States; Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States.

Fralin Biomedical Research Institute at Virginia Tech Carilion, 2 Riverside Circle, Roanoke, VA 24016, United States; Department of Statistics, Virginia Tech, Blacksburg, VA 24061, United States.

出版信息

Drug Alcohol Depend. 2022 May 1;234:109389. doi: 10.1016/j.drugalcdep.2022.109389. Epub 2022 Mar 9.

DOI:10.1016/j.drugalcdep.2022.109389
PMID:35287034
Abstract

BACKGROUND

Opioid use disorder (OUD) seriously impacts public health in the United States. However, few investigations of long-term outcomes following treatment with medication for OUD exist. Additionally, these studies have prioritized opioid use and treatment utilization outcomes, and a gap in knowledge regarding long-term, multidimensional trajectories of OUD recovery exists. This study investigated a diverse array of outcomes for individuals with OUD at an average of 4.2 years post clinical trial participation.

METHODS

Individuals who previously participated in long-acting buprenorphine subcutaneous injection clinical trials (NCT023579011; NCT025100142; NCT02896296) and enrolled in The Remission from Chronic Opioid Use-Studying Environmental and SocioEconomic Factors on Recovery (RECOVER; NCT03604861) Study participated in a follow up assessment (n = 216). Substance use, psychosocial, opioid dependence, and delay discounting outcomes were assessed. Regression analyses were conducted to determine significant associations between psychosocial/opioid dependence variables and both recent opioid use and delay discounting.

RESULTS

The majority of participants reported abstinence from opioids since the last RECOVER study assessment (mean 2.26 years; 55%) and in the past 30 days (69%). Participants reported low levels of depression and psychological distress. Positive associations between depression and opioid craving with past 30-day opioid misuse and delay discounting, and negative associations between quality of life and treatment effectiveness with these outcomes were observed.

CONCLUSIONS

This study examined longer term OUD recovery outcomes. Participants reported high levels of abstinence from opioids and psychosocial functioning. These encouraging results highlight the multidimensional nature of recovery from OUD, and further support the effectiveness of buprenorphine as an OUD treatment.

摘要

背景

阿片类药物使用障碍(OUD)严重影响美国的公共健康。然而,针对 OUD 药物治疗后的长期结果的研究很少。此外,这些研究优先考虑了阿片类药物的使用和治疗利用结果,而对于 OUD 康复的长期、多维轨迹的知识存在差距。本研究在平均 4.2 年的临床试验参与后,调查了 OUD 患者的一系列多样化结局。

方法

先前参加过长效丁丙诺啡皮下注射临床试验(NCT023579011;NCT025100142;NCT02896296)并参加了慢性阿片类药物使用缓解研究——环境和社会经济因素对康复的影响(RECOVER;NCT03604861)研究的个体参与了后续评估(n=216)。评估了物质使用、心理社会、阿片类药物依赖和延迟折扣结果。进行回归分析以确定心理社会/阿片类药物依赖变量与近期阿片类药物使用和延迟折扣之间的显著关联。

结果

大多数参与者报告自最后一次 RECOVER 研究评估以来(平均 2.26 年;55%)和过去 30 天内(69%)已戒除阿片类药物。参与者报告的抑郁和心理困扰程度较低。观察到抑郁和阿片类药物渴求与过去 30 天内阿片类药物滥用和延迟折扣之间存在正相关,而生活质量和治疗效果与这些结果之间存在负相关。

结论

本研究检查了 OUD 康复的长期结果。参与者报告了较高水平的阿片类药物戒断和心理社会功能。这些令人鼓舞的结果突出了 OUD 康复的多维性质,并进一步支持了丁丙诺啡作为 OUD 治疗的有效性。

相似文献

1
Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.阿片类药物使用障碍的康复:一项临床研究结束 4 年后的结局研究。
Drug Alcohol Depend. 2022 May 1;234:109389. doi: 10.1016/j.drugalcdep.2022.109389. Epub 2022 Mar 9.
2
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.阿片类使用障碍(OUD)经每月长效丁丙诺啡治疗后的康复:一项观察性研究 RECOVER 的 12 个月纵向结果。
J Addict Med. 2020 Sep/Oct;14(5):e233-e240. doi: 10.1097/ADM.0000000000000647.
3
Long-term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life.阿片类物质使用障碍的长期康复:康复亚组、过渡状态及其与物质使用、治疗和生活质量的关联。
Addiction. 2023 May;118(5):890-900. doi: 10.1111/add.16115. Epub 2023 Jan 10.
4
Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics.慢性阿片类药物使用缓解研究——探索环境和社会经济因素对康复的影响(RECOVER):研究设计和参与者特征。
Contemp Clin Trials. 2019 Jan;76:93-103. doi: 10.1016/j.cct.2018.11.015. Epub 2018 Nov 30.
5
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.丁丙诺啡缓释片延续治疗的获益:RECOVER 研究结果。
J Addict Med. 2023;17(2):182-189. doi: 10.1097/ADM.0000000000001070. Epub 2022 Sep 16.
6
Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids.多地点使用阿片类药物者的社会心理干预利用与物质滥用治疗结局。
J Subst Abuse Treat. 2020 May;112:68-75. doi: 10.1016/j.jsat.2020.01.016. Epub 2020 Jan 25.
7
Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.美沙酮使用与阿片类药物使用障碍急诊患者获得途径的差异:一项横断面研究。
J Subst Abuse Treat. 2021 Nov;130:108405. doi: 10.1016/j.jsat.2021.108405. Epub 2021 Apr 20.
8
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".先前的国家药物滥用治疗临床试验网络(CTN)阿片类药物使用障碍试验作为 NIDA CTN-0100“优化阿片类药物使用障碍药物治疗(RDD)的保留率、持续时间和停药策略”的背景和原理。
Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z.
9
Buprenorphine in the United States: Motives for abuse, misuse, and diversion.丁丙诺啡在美国:滥用、误用和转移的动机。
J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. Epub 2019 Jul 12.
10
Struggling With Recovery From Opioids: Who Is at Risk During COVID-19?从阿片类药物成瘾中恢复困难:在 COVID-19 期间谁有风险?
J Addict Med. 2023;17(3):e156-e163. doi: 10.1097/ADM.0000000000001096. Epub 2022 Oct 16.

引用本文的文献

1
The phenotype of recovery XII: A reinforcer pathology perspective on associations between delay discounting and pain catastrophizing in substance use disorder recovery.康复十二的表型:物质使用障碍康复中延迟折扣与疼痛灾难化之间关联的强化病理视角
J Subst Use Addict Treat. 2025 Feb;169:209573. doi: 10.1016/j.josat.2024.209573. Epub 2024 Nov 9.
2
The Phenotype of Recovery X: Associations between delay discounting, regulatory flexibility, and remission from substance use disorder.恢复 X 的表现:延迟折扣、调节灵活性与物质使用障碍缓解之间的关联。
J Subst Use Addict Treat. 2023 Dec;155:209122. doi: 10.1016/j.josat.2023.209122. Epub 2023 Jul 13.
3
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.
丁丙诺啡药物用于治疗阿片类物质使用障碍的发现、研发及美国食品药品监督管理局批准历程。
Drug Alcohol Depend Rep. 2023 Jan 10;6:100133. doi: 10.1016/j.dadr.2023.100133. eCollection 2023 Mar.